Literature DB >> 7554630

Ten years of experience with porous acetabular components for revision surgery.

L D Dorr1, Z Wan.   

Abstract

A prospective study was completed for 139 porous-coated revision acetabular components that were implanted with rim fit fixation and had a mean of 4.3 years' followup (range, 2-9.8 years). The Anatomic Porous Replacement component was studied. Harris Hip Scores were used for clinical evaluation, and the pain and limp components of the Harris Hip Score were assessed. Radiographic measurements were recorded as radiolucent lines by Delee and Charnley zones. Clinical results were of lesser value in this study because of the emphasis on the acetabular component. Of these components, 4.3% had revision; only 2 (1.4%) were revised for loosening. Migration occurred in 2.1% of these acetabular components. In the first 2 years postoperatively, 17.4% of components had increased radiolucent lines and 9.4% had fewer radiolucent lines. After 2 years, fixation was stable: 4% had progressively more radiolucent lines and 2% fewer radiolucent lines. The authors could not show any statistical difference in radiographic fixation of these components when adjunctive screw fixation was used or not used. Fixation of the acetabular components was better when slurry bone graft was not used to layer the acetabular surface. Fixation was similar whether the rim fit was obtained with or without protrusion of the medial dome of the cup into the pelvis. The authors did not observe osteolysis in the acetabular bone surrounding these components.

Entities:  

Mesh:

Year:  1995        PMID: 7554630

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  19 in total

1.  Highly crosslinked polyethylene does not reduce aseptic loosening in cemented THA 10-year findings of a randomized study.

Authors:  Per-Erik Johanson; Georgios Digas; Peter Herberts; Jonas Thanner; Johan Kärrholm
Journal:  Clin Orthop Relat Res       Date:  2012-11       Impact factor: 4.176

2.  Large acetabular defects can be managed with cementless revision components.

Authors:  E Scott Paxton; James A Keeney; William J Maloney; John C Clohisy
Journal:  Clin Orthop Relat Res       Date:  2011-02       Impact factor: 4.176

3.  Relationship between the pelvic osteolytic volume on computed tomography and clinical outcome in patients with cementless acetabular components.

Authors:  Ho Hyun Yun; Won Yong Shon; Suk Joo Hong; Jung-Ro Yoon; Jae-Hyuk Yang
Journal:  Int Orthop       Date:  2010-10-07       Impact factor: 3.075

4.  Type III acetabular defect revision with bilobed components: five-year results.

Authors:  Joseph T Moskal; Michael E Higgins; Joseph Shen
Journal:  Clin Orthop Relat Res       Date:  2008-02-10       Impact factor: 4.176

5.  Combined anteversion technique for total hip arthroplasty.

Authors:  Lawrence D Dorr; Aamer Malik; Manish Dastane; Zhinian Wan
Journal:  Clin Orthop Relat Res       Date:  2008-11-01       Impact factor: 4.176

6.  Do jumbo cups cause hip center elevation in revision THA? A computer simulation.

Authors:  Chima Nwankwo; Nick N Dong; Christopher D Heffernan; Michael D Ries
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

7.  [Five-year survival rate of the Allofit titanium press-fit cup].

Authors:  K Schroeder; A Moehlenbruch; M Zimmermann-Stenzel; D Parsch
Journal:  Orthopade       Date:  2010-01       Impact factor: 1.087

8.  Polyethylene in total hip arthroplasty: half a century in the limelight.

Authors:  Eduardo García-Rey; Eduardo García-Cimbrelo
Journal:  J Orthop Traumatol       Date:  2010-05-27

9.  Metal-on-metal hip arthroplasty does equally well in osteonecrosis and osteoarthritis.

Authors:  Manish R Dastane; William T Long; Zhinian Wan; Lisa Chao; Lawrence D Dorr
Journal:  Clin Orthop Relat Res       Date:  2008-03-19       Impact factor: 4.176

10.  Acetabular revision using a total acetabular allograft.

Authors:  Rajesh Malhotra; Vijay Kumar
Journal:  Indian J Orthop       Date:  2009-04       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.